MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$14,307K
Net Income
-$20,631K
Net Profit Margin
-144.20%
EPS
-$0.13
Unit: Thousand (K) dollars
Revenue Breakdown
Toripalimab
Product And Service Other
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net revenue
14,307
12,310
12,748
11,571
Cost of goods sold
4,242
3,814
4,045
3,721
Research and development
21,442
21,543
30,974
27,252
Selling, general and administrative
20,954
23,104
23,609
24,931
Total costs and expenses
46,638
48,461
58,628
55,904
Loss from operations
-32,331
-36,151
-45,880
-44,333
Interest expense
2,323
2,186
2,249
2,325
Loss on debt extinguishment
-
-
0
-
Other income (expense), net
1,307
1,402
1,782
2,141
Loss from continuing operations before income taxes
-33,347
-36,935
-46,347
-44,517
Net loss from continuing operations
-33,347
-36,935
-46,347
-44,517
Net revenue
12,824
-899
25,978*
10,663
Cost of goods sold
-
55
16,503*
287
Research and development
10
-
-985*
564
Selling, general and administrative
-213
50
7,567*
326
Total costs and expenses
-203
105
23,084*
1,177
Income from operations
13,027
-1,004
2,894*
9,486
Interest expense
-
-
2,023*
-
Loss (gain) on sale transactions, net
-311
-388
-886*
-422
Gain on debt extinguishment
-
-
20,572*
-
Other income (expense), net
-
-
-11,852*
-78
Net income from discontinued operations before income taxes
12,716
-1,392
8,704
8,986
Net income from discontinued operations, net of tax (note 6)
12,716
-1,392
8,704
8,986
Net income (gain)
-20,631
-38,327
-37,643
-35,531
Basic EPS
-0.13
-0.28
-0.313
-0.31
Diluted EPS
-0.13
-0.28
-0.313
-0.31
Basic Average Shares
154,816,912
136,398,303
120,409,168
116,229,170
Diluted Average Shares
154,816,912
136,398,303
120,409,168
116,229,170
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Selling, general and
administrative
-$213K
(-110.51%↓ Y/Y)
Net revenue
$12,824K
(25.06%↑ Y/Y)
Total costs and
expenses
-$203K
(-102.25%↓ Y/Y)
Research and development
$10K
(-97.73%↓ Y/Y)
Income from operations
$13,027K
(-7.47%↓ Y/Y)
Net income from
discontinued operations...
$12,716K
(-96.29%↓ Y/Y)
Loss (gain) on sale
transactions, net
-$311K
(-100.09%↓ Y/Y)
Net income (gain)
-$20,631K
(-106.93%↓ Y/Y)
Net income from
discontinued operations, net...
$12,716K
(-96.29%↓ Y/Y)
Net loss from
continuing operations
-$33,347K
(25.67%↑ Y/Y)
Loss from continuing
operations before income...
-$33,347K
(25.67%↑ Y/Y)
Other income
(expense), net
$1,307K
(-54.95%↓ Y/Y)
Toripalimab
$13,613K
(36.69%↑ Y/Y)
Product And Service
Other
$694K
(135.25%↑ Y/Y)
Loss from operations
-$32,331K
(28.92%↑ Y/Y)
Interest expense
$2,323K
(2.02%↑ Y/Y)
Net revenue
$14,307K
(39.53%↑ Y/Y)
Total costs and
expenses
$46,638K
(-16.33%↓ Y/Y)
Research and development
$21,442K
(-18.49%↓ Y/Y)
Selling, general and
administrative
$20,954K
(-19.53%↓ Y/Y)
Cost of goods sold
$4,242K
(24.95%↑ Y/Y)
Buy us a coffee
Coherus Oncology, Inc. (CHRS)
Coherus Oncology, Inc. (CHRS)